Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):713-726. doi: 10.3760/cma.j.cn121090-20240611-00217.
Chronic graft-versus-host disease (cGVHD) is a common and severe complication following allogeneic hematopoietic stem cell transplantation, which significantly impacts patients' survival and quality of life. In recent years, notable progress has been made in the diagnosis, prevention, and treatment of cGVHD, driven by the emergence of novel therapies such as targeted drugs and the advancement of clinical research. This consensus, based on the latest developments in cGVHD research and growing data from evidence-based medicine, has been revised and updated from the "Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (2021)" to better guide clinical practice.
慢性移植物抗宿主病（cGVHD）是异基因造血干细胞移植后常见且严重的并发症，显著影响患者的生存和生活质量。近年来，在靶向药物等新型疗法的出现以及临床研究进展的推动下，cGVHD的诊断、预防和治疗取得了显著进展。基于cGVHD研究的最新进展以及循证医学不断增加的数据，本共识已从《慢性移植物抗宿主病诊断与治疗中国专家共识（2021年版）》修订更新，以更好地指导临床实践。
